Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Katherine Davis

Pediatrics Willard, MO Medical Doctor

NPI 1649731977 CMS profile 11431556

502 S Miller Rd, Willard, MO 65781

Open in the dashboard

General payments

$779

40 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Davis of Willard, MO is reported in the CMS Open Payments database as having received $779 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $439 22
2024 General $238 13
2023 General $72 4
2022 General $31 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Davis
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Katherine Davis were reported at $439. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Katherine Davis Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $0 $49 $22–$110 $114
2021 $0 $68 $27–$158 $132
2022 $31 $77 $30–$173 $149
2023 $72 $88 $33–$190 $160
2024 $238 $94 $34–$206 $164
2025 $439 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $211 10 payments
  2. Globus Medical, Inc. $108 3 payments
  3. Exact Sciences Corporation $98 6 payments
  4. Merck Sharp & Dohme Corporation $74 5 payments
  5. GlaxoSmithKline, LLC. $50 3 payments
  6. Otsuka America Pharmaceutical, Inc. $49 3 payments
  7. Pfizer Inc. $40 2 payments
  8. Sanofi Pasteur Inc. $37 2 payments
  9. Sun Pharmaceutical Industries Inc. $31 1 payment
  10. Novartis Pharmaceuticals Corporation $19 1 payment
  11. Other $60 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $779 40 payments
Products named General payments · program years 2022–2025
  1. Wegovy $111 5 payments
  2. Senza $108 3 payments
  3. RYBELSUS $100 5 payments
  4. Ozempic $100 5 payments
  5. Cologuard Collection Kit $98 6 payments
  6. GARDASIL 9 $74 5 payments
  7. VAXNEUVANCE $59 4 payments
  8. BEXSERO $50 3 payments
  9. REXULTI $49 3 payments
  10. PAXLOVID $40 2 payments
  11. Other $286 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

665

Median for Pediatric Medicine: 38

Drug cost

$24,016

Median for Pediatric Medicine: $2,769

Branded share of claims

18.5%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 14 $13,302
Spiriva Respimat Tiotropium Bromide Brand 11 $5,707
Albuterol Sulfate Hfa Albuterol Sulfate Brand 17 $495
Tramadol Hcl Generic 16 $378
Atorvastatin Calcium Generic 65 $362
Pregabalin Generic 14 $322
Gabapentin Generic 28 $306
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 17 $273
Omeprazole Generic 34 $255
Valsartan Generic 22 $237

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $40
$40 — —
PAXLOVID
  • PFIZER INC. $23
$23 — —
RYBELSUS
  • Novo Nordisk Inc $20
$20 14 —
Ozempic
  • Novo Nordisk Inc $20
$20 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record